Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Zevra Therapeutics has recently attracted acquisition interest around its SDX portfolio, with reports indicating that Commave Therapeutics is evaluating the asset as a potential strategic purchase.</li><li>The SDX portfolio, which includes products such as AZSTARYS and related intellectual property and royalty streams, represents a differentiated set of assets within Zevra’s broader rare disease platform.</li><li>While Zevra has increasingly focused its corporate strategy on rare diseases—highlighted by the commercial launch of MIPLYFFA for Niemann-Pick disease type C (NPC) and the development of celiprolol for vascular Ehlers-Danlos syndrome—the SDX assets remain an attractive opportunity for companies seeking exposure to neurology and central nervous system therapeutics.</li></ul>

Zevra Therapeutics has recently attracted acquisition interest around its SDX portfolio, with reports indicating that Commave Therapeutics is evaluating the asset as a potential strategic purchase.The SDX portfolio, which includes products such as AZSTARYS and related intellectual property and royalty streams, represents a differentiated set of assets within Zevra’s broader rare disease platform.While Zevra has increasingly focused its corporate strategy on rare diseases—highlighted by the commercial launch of MIPLYFFA for Niemann-Pick disease type C (NPC) and the development of celiprolol for vascular Ehlers-Danlos syndrome—the SDX assets remain an attractive opportunity for companies seeking exposure to neurology and central nervous system therapeutics.

Zevra Therapeutics Sparks Buyout Buzz: Why Commave Therapeutics Is Eyeing Its SDX Portfolio!

<ul><li>Zevra Therapeutics has recently seen its stock jump following renewed takeover speculation, spotlighting the company’s strategic value in the rare disease therapeutics space.</li><li>The catalyst was a Betaville alert reporting that Collegium Pharmaceuticals had previously explored acquiring Zevra but failed to secure the necessary financing.</li><li>This is not the first time Zevra has attracted M&A interest—Betaville had flagged potential acquisition talks weeks earlier.</li></ul>

Zevra Therapeutics has recently seen its stock jump following renewed takeover speculation, spotlighting the company’s strategic value in the rare disease therapeutics space.The catalyst was a Betaville alert reporting that Collegium Pharmaceuticals had previously explored acquiring Zevra but failed to secure the necessary financing.This is not the first time Zevra has attracted M&A interest—Betaville had flagged potential acquisition talks weeks earlier.

Zevra Therapeutics In M&A Spotlight As Collegium Walks Away—What’s Next?

United States

Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company focuses on melding science, data, and patient need to create transformational therapies for diseases with limited and no treatment options with unique, data-driven clinical, regulatory, and commercialization strategies. Zevra Therapeutics serves patients and healthcare professionals worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zevra Therapeutics (ZVRA US)

Zevra Therapeutics Sparks Buyout Buzz: Why Commave Therapeutics Is Eyeing Its SDX Portfolio!

Zevra Therapeutics has recently attracted acquisition interest around its SDX portfolio, with reports indicating that Commave Therapeutics is...

Baptista Research

Zevra Therapeutics In M&A Spotlight As Collegium Walks Away—What’s Next?

Zevra Therapeutics has recently seen its stock jump following renewed takeover speculation, spotlighting the company’s strategic value in the rare...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)